{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:55:11Z","timestamp":1772762111783,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772840"],"award-info":[{"award-number":["81772840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10549-022-06679-0","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T03:21:01Z","timestamp":1662175261000},"page":"45-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression"],"prefix":"10.1007","volume":"196","author":[{"given":"Yuan-Ming","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Long","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Yuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Mian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Qin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Shen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Zi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3753-2900","authenticated-orcid":false,"given":"Xiao-Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"issue":"1","key":"6679_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F (2019) Breast cancer. Nat Rev Dis Primers 5(1):66. https:\/\/doi.org\/10.1038\/s41572-019-0111-2","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"6679_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s1470-2045(17)30904-x","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer J-U, Karn T, Pfitzner BM, K\u00fcmmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19(1):40\u201350. https:\/\/doi.org\/10.1016\/s1470-2045(17)30904-x","journal-title":"Lancet Oncol"},{"issue":"10","key":"6679_CR3","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Adams S, Disis ML (2016) Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol 2(10):1354\u20131360. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1061","journal-title":"JAMA Oncol"},{"key":"6679_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0165-6","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML (2016) Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-016-0165-6","journal-title":"J Immunother Cancer"},{"issue":"2","key":"6679_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, Fu YX (2018) PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Investig 128(2):580\u2013588. https:\/\/doi.org\/10.1172\/JCI96061","journal-title":"J Clin Investig"},{"issue":"26","key":"6679_CR6","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465","journal-title":"N Engl J Med"},{"issue":"5","key":"6679_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jaci.2018.02.042","volume":"142","author":"T Wieder","year":"2018","unstructured":"Wieder T, Eigentler T, Brenner E, Rocken M (2018) Immune checkpoint blockade therapy. J Allergy Clin Immunol 142(5):1403\u20131414. https:\/\/doi.org\/10.1016\/j.jaci.2018.02.042","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"6679_CR8","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974\u20131982. https:\/\/doi.org\/10.1200\/JCO.2014.59.4358","journal-title":"J Clin Oncol"},{"issue":"10","key":"6679_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020\u20131030. https:\/\/doi.org\/10.1200\/JCO.2013.53.0105","journal-title":"J Clin Oncol"},{"issue":"3","key":"6679_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","volume":"24","author":"LA Emens","year":"2018","unstructured":"Emens LA (2018) Breast cancer immunotherapy: facts and hopes. Clin Cancer Res 24(3):511\u2013520. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3001","journal-title":"Clin Cancer Res"},{"issue":"22","key":"6679_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, Investigators IMT (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"issue":"2","key":"6679_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00432-007-0278-x","volume":"134","author":"L Gaul","year":"2008","unstructured":"Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R (2008) Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells, the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 134(2):245\u2013253. https:\/\/doi.org\/10.1007\/s00432-007-0278-x","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"6679_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.20892\/j.issn.2095-3941.2018.0022","volume":"15","author":"MA Estiar","year":"2018","unstructured":"Estiar MA, Mehdipour P (2018) ATM in breast and brain tumors: a comprehensive review. Cancer Biol Med 15(3):210\u2013227. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2018.0022","journal-title":"Cancer Biol Med"},{"issue":"3","key":"6679_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/85798","volume":"27","author":"KK Khanna","year":"2001","unstructured":"Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27(3):247\u2013254","journal-title":"Nat Genet"},{"key":"6679_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.07.002","author":"MH Jin","year":"2019","unstructured":"Jin MH, Oh DY (2019) ATM in DNA repair in cancer. Pharmacol Ther. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.07.002","journal-title":"Pharmacol Ther"},{"issue":"6922","key":"6679_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature01368","volume":"421","author":"CJ Bakkenist","year":"2003","unstructured":"Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421(6922):499\u2013506","journal-title":"Nature"},{"issue":"11","key":"6679_CR17","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1093\/carcin\/bgq193","volume":"31","author":"V Stagni","year":"2010","unstructured":"Stagni V, Mingardi M, Santini S, Giaccari D, Barila D (2010) ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis. Carcinogenesis 31(11):1956\u20131963. https:\/\/doi.org\/10.1093\/carcin\/bgq193","journal-title":"Carcinogenesis"},{"issue":"8","key":"6679_CR18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/nm.2846","volume":"18","author":"Y Okuno","year":"2012","unstructured":"Okuno Y, Nakamura-Ishizu A, Otsu K, Suda T, Kubota Y (2012) Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat Med 18(8):1208\u20131216. https:\/\/doi.org\/10.1038\/nm.2846","journal-title":"Nat Med"},{"issue":"6","key":"6679_CR19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/1535-7163.MCT-12-0707","volume":"12","author":"MA Batey","year":"2013","unstructured":"Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NM, Lau A, Newell DR, Curtin NJ (2013) Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol Cancer Ther 12(6):959\u2013967. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0707","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"6679_CR20","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-12-3408","volume":"19","author":"L Biddlestone-Thorpe","year":"2013","unstructured":"Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NC, Tokarz M, Adams BR, Wagner AF, Khalil A, Gilfor D, Golding SE, Deb S, Temesi DG, Lau A, O\u2019Connor MJ, Choe KS, Parada LF, Lim SK, Mukhopadhyay ND, Valerie K (2013) ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res 19(12):3189\u20133200. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3408","journal-title":"Clin Cancer Res"},{"issue":"15","key":"6679_CR21","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","volume":"79","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, Parsels LA, Shi J, Ramnath N, Wahl DR, Pasca di Magliano M, Frankel TL, Kryczek I, Lei YL, Lawrence TS, Zou W, Morgan MA (2019) Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. Cancer Res 79(15):3940\u20133951. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0761","journal-title":"Cancer Res"},{"issue":"24","key":"6679_CR22","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.1002\/cam4.3552","volume":"9","author":"M Joshi","year":"2020","unstructured":"Joshi M, Grivas P, Mortazavi A, Monk P, Clinton SK, Sue-Ann Woo M, Holder SL, Drabick JJ, Yin M (2020) Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1\/PD-L1-treated advanced urothelial cancer. Cancer Med 9(24):9365\u20139372. https:\/\/doi.org\/10.1002\/cam4.3552","journal-title":"Cancer Med"},{"issue":"4","key":"6679_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41419-018-0458-4","volume":"9","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Li H, Deng Y, Tai Y, Zeng K, Zhang Y, Liu W, Zhang Q, Yang Y (2018) Cancer-associated fibroblasts induce PD-L1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis 9(4):422. https:\/\/doi.org\/10.1038\/s41419-018-0458-4","journal-title":"Cell Death Dis"},{"issue":"17","key":"6679_CR24","doi-asserted-by":"publisher","first-page":"17224","DOI":"10.1074\/jbc.M311875200","volume":"279","author":"CS Shi","year":"2004","unstructured":"Shi CS, Kehrl JH (2004) Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation. J Biol Chem 279(17):17224\u201317231. https:\/\/doi.org\/10.1074\/jbc.M311875200","journal-title":"J Biol Chem"},{"issue":"7","key":"6679_CR25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/PAS.0000000000001264","volume":"43","author":"H Reis","year":"2019","unstructured":"Reis H, Serrette R, Posada J, Lu V, Chen YB, Gopalan A, Fine SW, Tickoo SK, Sirintrapun SJ, Iyer G, Funt SA, Teo MY, Rosenberg JE, Bajorin DF, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA (2019) PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies. Am J Surg Pathol 43(7):920\u2013927","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"6679_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/jmcb\/mjs048","volume":"4","author":"M Sun","year":"2012","unstructured":"Sun M, Guo X, Qian X, Wang H, Yang C, Brinkman KL, Serrano-Gonzalez M, Jope RS, Zhou B, Engler DA, Zhan M, Wong ST, Fu L, Xu B (2012) Activation of the ATM-Snail pathway promotes breast cancer metastasis. J Mol Cell Biol 4(5):304\u2013315. https:\/\/doi.org\/10.1093\/jmcb\/mjs048","journal-title":"J Mol Cell Biol"},{"issue":"2","key":"6679_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259\u2013271","journal-title":"Ann Oncol"},{"issue":"3","key":"6679_CR28","doi-asserted-by":"publisher","first-page":"e60046","DOI":"10.1371\/journal.pone.0060046","volume":"8","author":"XL Qian","year":"2013","unstructured":"Qian XL, Li YQ, Yu B, Gu F, Liu FF, Li WD, Zhang XM, Fu L (2013) Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation. PLoS ONE 8(3):e60046. https:\/\/doi.org\/10.1371\/journal.pone.0060046","journal-title":"PLoS ONE"},{"issue":"1","key":"6679_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41598-019-57094-3","volume":"10","author":"X Zhu","year":"2020","unstructured":"Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, Di G, Liu G, Yu K, Shao Z, Wang Z (2020) The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep 10(1):225. https:\/\/doi.org\/10.1038\/s41598-019-57094-3","journal-title":"Sci Rep"},{"issue":"6","key":"6679_CR30","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s11523-018-0610-1","volume":"13","author":"QF Manson","year":"2018","unstructured":"Manson QF, Ter Hoeve ND, Buerger H, Moelans CB, van Diest PJ (2018) PD-1 and PD-L1 expression in male breast cancer in comparison with female breast cancer. Target Oncol 13(6):769\u2013777. https:\/\/doi.org\/10.1007\/s11523-018-0610-1","journal-title":"Target Oncol"},{"issue":"2","key":"6679_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S1471-4906(01)02118-4","volume":"23","author":"CV Ramana","year":"2002","unstructured":"Ramana CV, Pilar Gil M, Schreiber RD, Stark GR (2002) Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23(2):96\u2013101","journal-title":"Trends Immunol"},{"issue":"7668","key":"6679_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA (2017) Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548(7668):466\u2013470. https:\/\/doi.org\/10.1038\/nature23470","journal-title":"Nature"},{"issue":"6","key":"6679_CR33","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1074\/jbc.M114.616748","volume":"290","author":"H Xiao","year":"2015","unstructured":"Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C, Houghton PJ, Lin J (2015) A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells. J Biol Chem 290(6):3418\u20133429. https:\/\/doi.org\/10.1074\/jbc.M114.616748","journal-title":"J Biol Chem"},{"issue":"2","key":"6679_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.canlet.2014.04.006","volume":"349","author":"C-Y Huang","year":"2014","unstructured":"Huang C-Y, Tai W-T, Hsieh C-Y, Hsu W-M, Lai Y-J, Chen L-J, Shiau C-W, Chen K-F (2014) A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3. Cancer Lett 349(2):136\u2013143. https:\/\/doi.org\/10.1016\/j.canlet.2014.04.006","journal-title":"Cancer Lett"},{"issue":"9","key":"6679_CR35","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1158\/0008-5472.CAN-13-3470","volume":"74","author":"P Maycotte","year":"2014","unstructured":"Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A (2014) STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res 74(9):2579\u20132590. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3470","journal-title":"Cancer Res"},{"issue":"3","key":"6679_CR36","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.18632\/oncotarget.2748","volume":"6","author":"X Zhang","year":"2015","unstructured":"Zhang X, Tang J, Zhi X, Xie K, Wang W, Li Z, Zhu Y, Yang L, Xu H, Xu Z (2015) miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3\/VEGF-A pathway in gastric cancer. Oncotarget 6(3):1605\u20131617","journal-title":"Oncotarget"},{"key":"6679_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-015-0195-z","author":"FB Kang","year":"2015","unstructured":"Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG, Sun DX (2015) B7\u2013H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2\/STAT3\/Slug signaling pathway. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-015-0195-z","journal-title":"Cancer Cell Int"},{"issue":"1","key":"6679_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.20892\/j.issn.2095-3941.2019.0262","volume":"17","author":"K Jiao","year":"2020","unstructured":"Jiao K, Zhen J, Wu M, Teng M, Yang K, Zhou Q, Hu C, Zhou M, Li Y, Li Z (2020) 27-Hydroxycholesterol-induced EndMT acts via STAT3 signaling to promote breast cancer cell migration by altering the tumor microenvironment. Cancer Biol Med 17(1):88\u2013100. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2019.0262","journal-title":"Cancer Biol Med"},{"issue":"3","key":"6679_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11060-015-1731-3","volume":"123","author":"SD Ferguson","year":"2015","unstructured":"Ferguson SD, Srinivasan VM, Heimberger AB (2015) The role of STAT3 in tumor-mediated immune suppression. J Neuro oncol 123(3):385\u2013394. https:\/\/doi.org\/10.1007\/s11060-015-1731-3","journal-title":"J Neuro oncol"},{"key":"6679_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7285","author":"B Grabner","year":"2015","unstructured":"Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, Poli V, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Gyorffy B, Penninger JM, Popper H, Casanova E (2015) Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms7285","journal-title":"Nat Commun"},{"key":"6679_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8736","author":"J Pencik","year":"2015","unstructured":"Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marie IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Kramer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L (2015) STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms8736","journal-title":"Nat Commun"},{"issue":"10","key":"6679_CR42","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41375-019-0458-0","volume":"33","author":"YL Chen","year":"2019","unstructured":"Chen YL, Tang C, Zhang MY, Huang WL, Xu Y, Sun HY, Yang F, Song LL, Wang H, Mu LL, Li MH, Zheng WW, Miao Y, Ding LX, Li BS, Shen SH, Liu SL, Li H, Zhu ZQ, Chen HW, Tang ZH, Chen J, Hong DL, Chen HZ, Duan CW, Zhou BS (2019) Blocking ATM-dependent NF-kappaB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia. Leukemia 33(10):2365\u20132378. https:\/\/doi.org\/10.1038\/s41375-019-0458-0","journal-title":"Leukemia"},{"issue":"5721","key":"6679_CR43","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1126\/science.1108297","volume":"308","author":"JH Lee","year":"2005","unstructured":"Lee JH, Paull TT (2005) ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308(5721):551\u2013554. https:\/\/doi.org\/10.1126\/science.1108297","journal-title":"Science"},{"issue":"47","key":"6679_CR44","doi-asserted-by":"publisher","first-page":"45680","DOI":"10.1074\/jbc.M204255200","volume":"277","author":"SJ Schreiner","year":"2002","unstructured":"Schreiner SJ, Schiavone AP, Smithgall TE (2002) Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 277(47):45680\u201345687. https:\/\/doi.org\/10.1074\/jbc.M204255200","journal-title":"J Biol Chem"},{"issue":"2","key":"6679_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1083\/jcb.200911156","volume":"190","author":"S Giunta","year":"2010","unstructured":"Giunta S, Belotserkovskaya R, Jackson SP (2010) DNA damage signaling in response to double-strand breaks during mitosis. J Cell Biol 190(2):197\u2013207. https:\/\/doi.org\/10.1083\/jcb.200911156","journal-title":"J Cell Biol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06679-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06679-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06679-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:35:45Z","timestamp":1665405345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06679-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6679"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06679-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Tianjin Medical University Cancer Institute and Hospital (Date: March 27, 2020\/No:Ek2020146).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0a\u2013p.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}